Head-to-head · Cost-Efficiency Index
MyStart Health vs Evernow
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
MyStart Health
Shoppers who want a single flat all-inclusive monthly price and don't need semaglutide vs. tirzepatide broken out separately.
Visit MyStart HealthEvernow
Cost-first shoppers who want women 40+ wanting GLP-1 prescribing integrated with menopause/hormone care, ideally with insurance.
Visit EvernowThe verdict
MyStart Health and Evernow tie on the Cost-Efficiency Index at 49/100, so neither wins outright on the numbers. For most shoppers we'd start with MyStart Health (ranked #418, a hair above #421) — Shoppers who want a single flat all-inclusive monthly price and don't need semaglutide vs. tirzepatide broken out separately. But Evernow is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs MyStart Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | MyStart Health | Evernow |
|---|---|---|
| Cost-Efficiency Index | 49/100 | 49/100 |
| Semaglutide / mo | $299/mo (compounded) | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | $3,588 | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #418 | #421 |
MyStart Health
49/100Where the value is
- Genuinely all-inclusive stated price: physician evaluations, unlimited follow-ups, bloodwork, and shipping are explicitly bundled into the $299 figure with 'no hidden fees'
- Price-lock guarantee explicitly covers dose increases — the FAQ states the price won't rise 'even if your dosage increases'
- Named Chief Medical Advisor (Dr. Ritu Chopra, Beverly Hills MD)
The tradeoffs
- Does not publish separate pricing for semaglutide vs. tirzepatide — $299 is a single blended program price, so it's unclear which drug (or whether both) that figure actually buys
- A sitewide 'Lifetime 25% Off' promo banner is not reconciled against the stated '$299/month excluding any discounts' base price or the price-lock guarantee's 'excluding our first-time discount' exception — genuinely ambiguous what a patient ends up paying long-term
Regulatory note: the FDA issued a warning letter to Matthew Stern, CEO MyStart Health LLC. in September 2025. We still list and link to MyStart Health; you should know the letter is on the public record before you decide.
Evernow
49/100Where the value is
- Confirmed genuine GLP-1 prescribing (not hormone-therapy-only, despite the brand's menopause focus)
- Only prescribes FDA-approved branded medications, no compounded-drug quality uncertainty
- Available in all 50 states plus D.C.
The tradeoffs
- No cash-pay price published anywhere -- cost is insurance-dependent and opaque to uninsured shoppers
- No compounded option for patients priced out of branded GLP-1s
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.